Drug Trial Radar · NCT03758664
Clinical Study of ICP-192 in Solid Tumors Patients
Last checked: Nov 19, 2026Latest source record: Jul 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
56
Planned (sponsor's estimate)
Start
Dec 19, 2018
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label, non-randomized, Phase I/IIa, dose-escalating, dose-extension, first-in-man study.
Conditions
- Solid Tumor
Interventions
ICP-192Drug
Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified "3+3" dose escalation scheme,
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events(Phase 1 dose escalation)Time frame: From the time a signed and dated ICF until 28 days after last dose of study drug
- Objective Response Rate(ORR)(Phase 2a dose expansion)Time frame: At the end of Cycle 4(each cycle is 21 days)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
ZhuJiang Hospital of Southern Medical University
Guangzhou, Guangdong, China · Not yet recruiting
Henan cancer hospital & Affiliated Tumor Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Hunan cancer hospital & the affiliated cancer hospital of xiangya school of medicine ,central south university
Changsha, Hunan, China · Not yet recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Not yet recruiting
The First Bethune Hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Cancer hospital of the university of Chinese academy of sciences
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.